Which antiplatelet monotherapy is best for CAD secondary prevention?
International researchers say the status of aspirin as the mainstay of antiplatelet therapy 'has been challenged'.
Antiplatelet monotherapy with clopidogrel or ticagrelor may be safer and more effective for secondary prevention of cardiovascular events than aspirin alone, results from a large meta-analysis show.
The team of international doctors report that adults with coronary artery disease (CAD) given a P2Y12 inhibitor as the sole antithrombotic agent had a 12% lower risk of cardiovascular death, MI and stroke than those given aspirin.
